U.K. Drug Risk-Sharing Schemes Eyed Warily By Parliamentary Committee
Executive Summary
Pharmaceutical risk-sharing schemes, in which the government payer and manufacturer split the potential cost of a new or unproven therapy, should be approached cautiously, the U.K. Health Select Committee recommends in a new report
You may also be interested in...
Velcade Rebate Scheme In U.K. Sets Up Broader Cost-Effectiveness Review
An innovative cost-sharing arrangement in which Johnson & Johnson will rebate the cost of the cancer drug Velcade (bortezomib) when patients have a minimal response will be implemented in the U.K. by early 2008
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.